Professor David Nutt: The Therapeutic Use of Psychedelics

During The PSYCH Symposium in November 2020, Professor David Nutt, chairman of Awakn Life Sciences, founder of Drug Science and the director of neuropsychopharmacology at Imperial College London, delivered a virtual keynote speech on ...

Gwella and the Untapped Opportunity In Functional Mushrooms

A new company straddling both the functional health and psychedelic space with a consumer/retail first approach. Backed by a leading team of scientists, doctors, investors and experts across the wellness space, the company has full ...

St. Vincent and the Grenadines Launch Psychedelics Initiative

Exclusive: Saint Vincent and the Grenadines announces initiative to permit psychedelic treatment and research  The Caribbean nation of Saint Vincent and the Grenadines has launched an initiative to permit and support psychedelic ...

Compass Pathways’ IPO could signal a prosperous future

For the first time, stock in a psychedelic medicine company was traded on the market – and it was major success. Compass Pathways (NASDAQ: CMPS) went public by launching its IPO earlier this months and sold 7.5 million shares, ...

PSYCH talks to Ronan Levy on Field Trip going public

Field Trip Health Ltd. (CSE: FTRP) began trading shares on the Canadian Securities Exchange on Tuesday 6th October, opening at $3.50 Canadian Dollars and closing its first day at $2.70 Canadian Dollars. The public listing comes on the ...

Legal psychedelic therapies will offer healthcare cost savings of billions of dollars

While a number of states have begun to legalise the medical use of certain psychedelics, widespread legalisation is set to start taking place from 2021 onwards. The new global psychedelics industry will be poised to result in cost ...

Innovation in Psychedelics

This is a nascent and fast emerging industry, witnessing a flurry of commercial activity, including the founding of new companies, a number of IPO listings from established companies and a spate of M&A activity occurring on an ...

Consumer attitudes to Psychedelics for mental health

PSYCH by Prohibition Partners conducts proprietary research on consumer attitudes to psychedelics In May 2020, Prohibition Partners conducted a nationally representative consumer survey in the US and the UK, the aim of which was to ...

Digital therapeutics and telehealth set to transform psychedelic therapy

COVID-19 and the ‘new normal’ for healthcare provision  Pioneers and early movers in the psychedelics industry are using tech to a) develop bespoke therapies for patients which are individually tailored to treat their specific mental ...